We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App




Clinical Exome Sequencing Genetically Identifies Rare Mendelian Disorders

By LabMedica International staff writers
Posted on 28 Oct 2014
Print article
Illumina\'s HiSeq 2000 ultra-high-throughput sequencing system
The HiSeq 2000 ultra-high-throughput sequencing system (Photo courtesy of Illumina)
Advances in next-generation sequencing technologies have decreased the cost of sequencing per base pair about 10-fold, improved accuracy, and greatly increased the speed of generating sequence data.

Exome sequencing, which sequences the protein-coding region of the genome, has been rapidly applied to variant discovery and recent increases in accuracy have enabled development of clinical exome sequencing (CES) for mutation identification in patients with suspected genetic diseases.

Scientists at the University of California, Los Angeles (UCLA; CA, USA) performed clinical exome sequencing on 814 consecutive patients with undiagnosed, suspected genetic conditions. Clinical exome sequencing was conducted as trio-CES, both parents and their affected child sequenced simultaneously, to effectively detect de novo and compound heterozygous variants or as proband-CES with only the affected individual sequenced, when parental samples were not available.

Whole blood collected in tubes with anticoagulants or purified genomic DNA from tissue sources was accepted for testing. Genomic DNA extraction, library preparation, sequencing, and data analysis were performed using validated protocols. Exome capture was performed using SureSelect Human All Exon V2 Kit (Agilent Technologies; Santa Clara, CA, USA) and sequencing was performed using the HiSeq 2000 for a 50-bp paired-end run or HiSeq 2500 for a 100-bp paired-end run (Illumina; San Diego, CA, USA).

Of the 814 cases, the overall molecular diagnosis rate was 26%. The molecular diagnosis rate for trio-CES was 31% 1(27/410 cases), and 22% (74/338 cases) for proband-CES. In cases of developmental delay in 138 children, who were under five years of age, the molecular diagnosis rate was 41% (45/109), for trio-CES cases and 9% (2/23) for proband-CES cases. The significantly higher diagnostic yield of trio-CES was due to the identification of de novo and compound heterozygous variants.

Wayne W. Grody, MD, PhD, a professor of pathology and coauthor of the study, said, “All families deserve a clear diagnosis of their child's condition. Exome sequencing plays an important role in identifying the precise cause of a child's illness. This is immediately useful to families and physicians in understanding how the disease occurred, preventing unnecessary testing, and developing the best strategies to treat it.” The study was published on October 18, 2014, in Journal of the American Medical Association.

Related Links:

University of California, Los Angeles 
Agilent Technologies
Illumina


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.